The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utilization of precision oncology decision support for genomically-informed cancer therapy.
 
Amber Johnson
No Relationships to Disclose
 
Yekaterina Khotskaya
No Relationships to Disclose
 
Lauren Brusco
No Relationships to Disclose
 
Jia Zeng
No Relationships to Disclose
 
Vijaykumar Holla
No Relationships to Disclose
 
Ann Marie Bailey
No Relationships to Disclose
 
Beate Litzenburger
No Relationships to Disclose
 
Nora Sanchez
No Relationships to Disclose
 
Md Abu Shufean
No Relationships to Disclose
 
Sarina Anne Piha-Paul
Research Funding - Abbvie; Bayer; Biomarin; Cerulean Pharma; Curis; Five Prime Therapeutics; GlaxoSmithKline; Helix BioPharma; Incyte; Merck; Novartis; Principa Biopharma; Puma Biotechnology; Samumed; XuanZhu
 
Vivek Subbiah
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Bioxell Pharma (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
David S. Hong
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Mark Routbort
No Relationships to Disclose
 
Kenna Rael Shaw
No Relationships to Disclose
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena
Honoraria - AstraZeneca; Isis Pharmaceuticals; Lilly; Novartis; Nuevolution; Symphony Evolution
Consulting or Advisory Role - Adventis Health; AstraZeneca; Blend Therapeutics; Catena; Critical Outcome Technologies; HanAl Bio Korea; Immunome; Lilly; Millennium; Novartis; Nuevolution; Precision Medicine Research Associates, LLC; Provista Diagnostics; SignalChem; Symphony Evolution
Research Funding - AstraZeneca; Critical Outcome Technologies
Patents, Royalties, Other Intellectual Property - Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Immunome; Isis Pharmaceuticals; Lilly; MedImmune; Nuevolution
 
John Mendelsohn
Leadership - Merrimack
Stock and Other Ownership Interests - Merrimack
Consulting or Advisory Role - MedImmune; ZIOPHARM Oncology
Patents, Royalties, Other Intellectual Property - ImClone Systems; Lilly
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem